Form D · Pharmaceuticals

Rallybio Corp

New Haven, CT · CIK 0001739410

Offering snapshot reported Apr 22, 2024 · SEC filing

Reported sold
$6.6M
Offering amount: $6.6M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 10, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 22, 2024Initial$6,600,000No comparison1SEC filing
May 29, 2020Amendment$145,204,965$51,999,979vs Apr 13, 202028SEC filing
Apr 13, 2020Initial$93,204,986No comparison24SEC filing
May 7, 2018Initial$5,999,999No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-511203

Source: Form D, filed Apr 22, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Helen M. Boudreau Director
Wendy K. Chung Director
Jeffrey Fryer Executive
Robert Hopfner Director
Rob Hopfner Director
Ron Hunt Director
Ronald M. Hunt Director
Lucian Iancovici Director
Jonathan I. Lieber Executive
Hui Liu Director
Martin W. Mackay Director
Christine A. Nash Director
Kush M. Parmar Director
Ketan Patel Director
Tim Shannon Director
Paula Soteropoulos Director
Stephen Uden Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
234 Church Street Suite 1020
New Haven, CT, 06510